An Open-label, Randomized, Phase 1, Single-Dose Crossover Study to Evaluate Safety, Tolerability and Relative Bioavailability of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered in Healthy Subjects
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Pegvisomant (Primary)
- Indications Acromegaly
- Focus Pharmacokinetics
- Sponsors Pfizer
- 10 Oct 2017 New trial record